JAMM Therapeutics
Systemic Lupus Erythematosus Treatment
Health Tech & Life Sciences
Non Active, Jul 2024 ceased to operate
Company Overview
Snapshot
Founded in October 2019, JAMM Therapeutics operated with 1–10 employees. The company secured one funding round from two investors, FutuRx and RMGP Biopharma Investment Fund, before ceasing operations in July 2024.
Business overview
JAMM Therapeutics was a drug discovery company focused on developing a novel treatment approach for systemic lupus erythematosus. The company operated within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development, with a focus on biologicals for pharmaceutical applications.
Company Intelligence Q&A
- What was JAMM Therapeutics' primary focus?
- JAMM Therapeutics focused on drug discovery, specifically developing a novel treatment approach for systemic lupus erythematosus.
- When was JAMM Therapeutics founded?
- JAMM Therapeutics was founded in October 2019.
- What was the operational status of JAMM Therapeutics?
- JAMM Therapeutics ceased to operate in July 2024.
- Which investors participated in JAMM Therapeutics' funding round?
- In May 2020, JAMM Therapeutics received funding from FutuRx and RMGP Biopharma Investment Fund.
- In which sector did JAMM Therapeutics operate?
- JAMM Therapeutics operated in the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.